Carregant...
Phase I Trial of (90)Y-DOTA(0)-Tyr(3)-Octreotide Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
PURPOSE: Conduct a Phase I trial of (90)Y-DOTA(0)-Tyr(3)-octreotide to determine the dose/toxicity profile in children and young adults with somatostatin receptor positive tumors. METHODS: A 3×3 design was utilized to determine the highest tolerable dose of (90)Y-DOTA(0)-Tyr(3)-octreotide with admin...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3753801/ https://ncbi.nlm.nih.gov/pubmed/20847174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.110.075226 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|